Kouji Hirota

24PUBLICATIONS
31CO-AUTHORS
Haematological tumoursCancer geneticsMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jun 26, 2026
Common DNA Damage Response Factors Required for Cellular Resistance to Inhibitors for the Ataxia Telangiectasia and Rad3-Related Checkpoint Kinase in Hematopoietic Cells.

|Feb 27, 2026
Generation of Human Haematopoietic Model Cell Lines Revealed Distinct Replication Stress Tolerance Between Two Oncogenic KRAS Mutations, G12V and A146T.

Mone Okuda, Ryotaro Kawasumi, Kayoko Tanaka

|Dec 10, 2025
Targeting Genome Maintenance Defects of Cancers Using Chain-Terminating Nucleoside Analogs.

Ryotaro Kawasumi, Rubaiat E Tabassum, Kouji Hirota

|Jul 21, 2025
The flap endonuclease-1 promotes cellular tolerance to a chain-terminating nucleoside analog, alovudine, by counteracting the toxic effect of 53BP1.

Md Bayejid Hosen, Ryotaro Kawasumi, Kouji Hirota

|Feb 26, 2025
Monoclonal antibody generation by controlled immunoglobulin gene rearrangements.

Akiho Murayama, Shin Matsui, Takuya Abe

|Aug 22, 2024
RAD18- and BRCA1-dependent pathways promote cellular tolerance to the nucleoside analog ganciclovir.

Tasnim Ahmad, Ryotaro Kawasumi, Kouji Hirota

Pageof 4

Frequent Collaborators

4 joint publications

Ryotaro Kawasumi

2 joint publications

Kayoko Tanaka

2 joint publications

Masato T Kanemaki

1 joint publications

Michele Giannattasio